skip to page content

Arthur Tzianabos, Ph.D.
Venture Partner, 5AM Ventures & Chair of the Board for Homology Medicines

Arthur Tzianabos, Ph.D., has 30 years of experience in the biotechnology industry leading teams in the discovery, development, clinical translation and commercialization of new treatments for rare diseases. Most recently, Dr. Tzianabos served as President and CEO of Homology Medicines and is currently Chair of the Board. During his previous nine-year tenure at Shire, Dr. Tzianabos had an active role in the development, approval, and commercial launch of multiple therapies for patients with rare genetic disorders. He also worked closely with the Business Development and Corporate Venture functions to invest in and acquire new companies and technologies to build Shire’s pipeline. Dr. Tzianabos was an Associate Professor of Medicine at Harvard Medical School and maintained laboratories at the Channing Laboratory, Brigham and Women’s Hospital and the Department of Microbiology and Molecular Genetics at Harvard Medical School. In addition to Homology, he is also Chair of the Board for Akouos Therapeutics, a member of the Board of Directors for both Stoke Therapeutics and Oxford Biomedica Solutions, serves on the Development Board for the University of New Hampshire’s College of Life Sciences and Agriculture and is a member of the Alliance for Regenerative Medicine’s Board of Directors and Executive Committee. He has published more than 80 scientific papers, reviews, book chapters and patents. Dr. Tzianabos holds a B.S. in Biology from Boston College and a Ph.D. in Microbiology from the University of New Hampshire.